Neoadjuvant HER2+ Articles

Managing Cardiac AEs in HER2-Positive Breast Cancer
Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.
Dual Targeting Advances in HER2+/HR+ Breast Cancer
The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.
Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs
Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.
Blood Test May Predict Palbociclib Response Earlier in Breast Cancer
A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance). 
European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer
European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.
Expert Highlights Evolving Options in HER2+ Breast Cancer
Tiffany A. Traina, MD, discusses her experiences with using neratinib and pertuzumab, and shares her excitement on the direction in which the HER2-positive breast cancer field is moving.
Blackwell Sheds Light on Recent Advances in HER2+ Breast Cancer
Kimberly L. Blackwell, MD, discusses novel agents and other recent advancements in the treatment paradigm of HER2-positive breast cancer.
Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer
The neoadjuvant combination of palbociclib (Ibrance), pertuzumab (Perjeta), fulvestrant (Faslodex), and trastuzumab (Herceptin), cut expression of Ki67 and induced an overall clinical response of 29% in women with ER-positive/HER2-positive breast cancer.
Tucatinib Combo Explored in HER2-Positive Breast Cancer
Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.
Trastuzumab Biosimilar Demonstrates Equivalence in HER2+ Breast Cancer
The trastuzumab (Herceptin) biosimilar SB3 induced a rate of breast pathologic complete response similar to trastuzumab in women with HER2-positive breast cancer, according to results from a phase III study of 800 patients.
Publication Bottom Border
Border Publication